This site is intended for UK healthcare professionals only

Diabetes Professional Care
15-16 October 2024, Olympia London

The UK's leading event for the entire team involved in the prevention, treatment and management of diabetes and its related conditions.

Are you a UK healthcare professional?

We are unfortunately unable to allow patients to attend Diabetes Professional Care

If you would like more information on general practice or primary care, please refer to the NHS website.

Visit the NHS website

Legal Notice

DIABETES PROFESSIONAL CARE IS SUPPORTED BY THE PHARMACEUTICAL AND MED TECH INDUSTRIES VIA GRANTS, SPONSORSHIP, AND EXHIBITION PACKAGES. SESSIONS DELIVERED WITH INPUT FROM OUR SUPPORTERS WILL ALWAYS BE MARKED ON THE PROGRAMME.
A FULL LIST OF CONFIRMED SUPPORTERS FOR DIABETES PROFESSIONAL CARE CAN BE FOUND HERE.
 

DPC2024

Subpage Hero

     

Loading

Obesity pharmacotherapy - Where are we now?

15 Oct 2024
Nutrition & Lifestyle Clinic
Obesity pharmacotherapy - Where are we now?

Obesity is a chronic disease associated with serious complications and increased mortality. Until recently, bariatric surgery was the only intervention that consistently resulted in ≥15% WL and maintenance. Our better understanding of the role of gut-brain axis on appetite regulation has led to the development over the last years of safe and effective medications for obesity management which are based on entero-pancreatic hormones, such as glucagon-like peptide-1 (GLP-1) receptor analogues (RAs). Semaglutide 2.4 mg once weekly is the latest approved GLP-1 RA for chronic weight management leading to 15-17% weight loss with evidence of cardioprotection. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies. The evidence behind the medications approved by NICE for obesity management, as well as the NICE criteria for their prescription will be discussed in this session.

Speakers
Dimitris Papamargaritis, Associate Professor in Diabetes and Endocrinology - University of Leicester

Sponsors

Diamond sponsor

 

Gold sponsor

Gold sponsor

Gold sponsor

Partners

Education Partner

Education Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Media Partner